Descartes-11

N/A

Report date: 2022/11/20 16:16:23

Base Information

Drug NameDescartes-11

Drug Alias NameDescartes-11Descartes-011

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-BCMA

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesCartesian Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCartesian Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A